Yuanyuan Xu

Nov 14, 2024 | chemistry-europe.onlinelibrary.wiley.com | Dan Li |Yi Wang |Yuanyuan Xu |Hongping Long

Supporting Information As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.

May 15, 2024 | dovepress.com | Jun Song |Ning Li |Ruihua Li |Yuanyuan Xu

IntroductionPneumonia is one of the most severe inflammatory diseases of the respiratory system.1 Pneumonia continues to be a common infectious disease which often results in hospital admissions and is occasionally lethal.2 Severe pneumonia is a widely-known disorder that intensive care physicians have to face.3 Severe pneumonia is a prevalent acute respiratory disorder in children, with a rapid onset and violent onset, and it often impacts the whole body.

Feb 17, 2024 | dovepress.com | Ningning Wang |Yuanyuan Xu |Guangde Yang |He Chen

Back to Journals » Journal of Hepatocellular Carcinoma » Volume 11 Authors Wang N , Xu Y, Yang G, Chen H, Wang X, Fu J, Li L, Pan X  Received 17 February 2024Accepted for publication 19 June 2024 Published 4 July 2024Volume 2024:11 Pages 1311—1321 DOI https://doi.org/10.2147/JHC.S464033Checked for plagiarism YesReview by Single anonymous peer reviewPeer reviewer comments 3 Editor who approved publication: Prof.

Jun 16, 2023 | pubs.rsc.org | Yuanyuan Xu |Siyuan Chen |Yuxin Zhang |Can Wu

Antibacterial Black Phosphorus Nanosheets for Biomedical Application Yuanyuan Xu,   Siyuan Chen,   Yuxin Zhang,   Can Wu,   Lei Li,   Xuefeng Hu,   Jieyu Zhang  and  Yunbing Wang   Abstract Bacterial infections pose a significant threat to human health and a heavy burden on the global healthcare system. Antibiotics are the primary treatment, but they may lead to bacterial resistance and adverse side effects.

May 26, 2023 | hindawi.com | Yuanyuan Xu |Zhixuan Li |Xian Jiang

Background. The pathogenesis of atopic dermatitis (AD) is associated with proinflammatory cytokines and the JAK/STAT signaling pathway. Upadacitinib, an approved oral JAK1 inhibitor, has been investigated in some clinical trials and observational studies of AD. However, the efficacy and safety profile of upadacitinib for AD is still unclear, as few previous meta-analyses evaluated upadacitinib alone. Purpose.